The 10-second takeaway
For the quarter ended June 30 (Q2), Bristol-Myers Squibb met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank. Non-GAAP earnings per share contracted. GAAP earnings per share dropped significantly.
Margins dropped across the board.
Bristol-Myers Squibb chalked up revenue of $4.05 billion. The 14 analysts polled by S&P Capital IQ hoped for revenue of $4.05 billion on the same basis. GAAP reported sales were 8.9% lower than the prior-year quarter's $4.44 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.44. The 17 earnings estimates compiled by S&P Capital IQ predicted $0.44 per share. Non-GAAP EPS of $0.44 for Q2 were 8.3% lower than the prior-year quarter's $0.48 per share. GAAP EPS of $0.32 for Q2 were 16% lower than the prior-year quarter's $0.38 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 72.6%, 270 basis points worse than the prior-year quarter. Operating margin was 18.0%, 910 basis points worse than the prior-year quarter. Net margin was 13.2%, 130 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $4.05 billion. On the bottom line, the average EPS estimate is $0.46.
Next year's average estimate for revenue is $16.34 billion. The average EPS estimate is $1.80.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,660 members out of 1,773 rating the stock outperform, and 113 members rating it underperform. Among 485 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 466 give Bristol-Myers Squibb a green thumbs-up, and 19 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is outperform, with an average price target of $46.25.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Bristol-Myers Squibb to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.